Fuller & Thaler Asset Management, Inc. Intercept Pharmaceuticals, Inc. Transaction History

Fuller & Thaler Asset Management, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$9.99 - $18.71 $75,124 - $140,699	-7,520 Reduced 3.73%	193,940 $3.6 Million
Q2 2023 Aug 14, 2023	BUY	$9.17 - $19.29 $1.85 Million - $3.89 Million	201,460 New	201,460 $2.23 Million
Q2 2022 Aug 12, 2022	BUY	$11.23 - $19.59 $12,353 - $21,549	1,100 Added 0.67%	165,310 $2.28 Million
Q1 2022 May 13, 2022	BUY	$13.37 - $17.79 $11,030 - $14,676	825 Added 0.5%	164,210 $2.67 Million
Q4 2021 Feb 09, 2022	BUY	$14.28 - $19.53 $2.33 Million - $3.19 Million	163,385 New	163,385 $2.66 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Fuller & Thaler Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Fuller & Thaler Asset Management, Inc. with notifications on news.